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Infections caused by Mycobacterium abscessus are increasing in prevalence in cystic fibrosis patients. 
This opportunistic pathogen′s intrinsic resistance to most antibiotics has perpetuated an urgent 
demand for new, more effective therapeutic interventions. Here we report a prospective advance in 
the treatment of M. abscessus infection; increasing the susceptibility of the organism to amoxicillin, 
by repurposing the β-lactamase inhibitor, relebactam, in combination with the front line M. abscessus 
drug imipenem. We establish by multiple in vitro methods that this combination works synergistically 
to inhibit M. abscessus. We also show the direct competitive inhibition of the M. abscessus β-lactamase, 
BlaMab, using a novel assay, which is validated kinetically using the nitrocefin reporter assay and in silico 
binding studies. Furthermore, we reverse the susceptibility by overexpressing BlaMab in M. abscessus, 
demonstrating relebactam-BlaMab target engagement. Finally, we highlight the in vitro efficacy of this 
combination against a panel of M. abscessus clinical isolates, revealing the therapeutic potential of the 
amoxicillin-imipenem-relebactam combination.
Mycobacterium abscessus is a rapidly growing, non-tuberculous mycobacteria (NTM) and increasingly preva-
lent opportunistic human pathogen. It is capable of causing pulmonary infections in patients with structural 
lung disorders such as cystic fibrosis (CF) and bronchiectasis as well as skin and soft tissue infections (SSTIs) in 
humans1–6. However, monitoring the incidence of M. abscessus infection is difficult, mainly due to incorrect or 
non-specific species identification (i.e. isolates being referred to as M. chelonae/abscessus group or simply non-
tuberculous mycobacteria) obscuring its true prevalence, which is estimated to be much higher than currently 
thought7,8.
As with other NTMs, M. abscessus is resistant to the frontline antibiotics used for tuberculosis treatment; 
rifampicin, ethambutol, pyrazinamide and isoniazid9–12. Despite reports that novel drugs developed to treat 
tuberculosis, such as bedaquiline and rifabutin may have some efficacy against M. abscessus, the paucity of availa-
ble and potential treatments for this disease remains clear13,14. Infection with M. abscessus is treated with a combi-
nation therapy of amikacin, tigecycline and imipenem, supplemented with oral clarithromycin or azithromycin, 
if the patient’s isolate is macrolide susceptible, for 1 month. This is followed by a 12-month continuation phase 
comprising of nebulised amikacin, and a combination of clofazimine, linezolid, minocycline, moxifloxacin or 
co-trimoxaole, once the patient′s isolate has been susceptibility tested15,16. The ubiquitous environmental nature 
of M. abscessus may go some way to explaining the high levels of intrinsic drug resistance to most major classes 
of antibiotic that is observed clinically17. As a consequence of this, the efficacy of the current drug regime is poor 
and often does not successfully treat M. abscessus infections16.
M. abscessus expresses an endogenous class A β-lactamase (BlaMab) conveying intrinsic resistance to a wide 
range of β-lactam antibiotics18. The identification of BlaMab, a homolog of the Mycobacterium tuberculosis endog-
enous β-lactamase, BlaC, sparked widespread investigation into the potential of β-lactamase inhibitors to sup-
plement the treatment of M. abscessus infection18. One of these studies demonstrated the inhibitory activity 
of avibactam, a non-β-lactam β-lactamase inhibitor, against BlaMab significantly improving the in vitro and in 
vivo activity of not only imipenem, but also amoxicillin, which often displays no activity against M. abscessus19. 
Avibactam is commercially available in combination with the cephalosporin ceftazidime, rather than imipenem20. 
1School of Life and Health Sciences, Aston University, Aston Triangle, B4 7ET, Birmingham, UK. 2Birmingham 
Children’s Hospital, Birmingham Women’s and Children’s NHS Foundation Trust, Steelhouse Lane, B4 6NH, 
Birmingham, UK. 3These authors contributed equally: Rose C. Lopeman and James Harrison. *email: J.a.g.cox@
aston.ac.uk
open
2Scientific RepoRtS |          (2020) 10:928  | https://doi.org/10.1038/s41598-020-57844-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
Recently, multiple studies have been published demonstrating a number of β-lactam combinations displaying 
high levels of in vitro synergistic activity against M. abscessus complex21,22. Furthermore, one of these studies iden-
tified the in vitro activity of two new non-β-lactam β-lactamase inhibitors, named relebactam and vaborbactam, 
which demonstrated synergistic activity between imipenem and relebactam as well as meropenem and vabor-
bactam23. This is important, since imipenem is currently used as a front line drug against M. abscessus infection, 
due to imipenem being the carbapenem with the highest activity against M. abscessus24. Therefore, increasing the 
susceptibility of M. abscessus to imipenem would have substantial clinical impact.
In this study, we have expanded upon previous work and identified a significant step forward in treatment 
potential for M. abscessus infection23. We demonstrate the in vitro increase in susceptibility of the organism to 
the broad spectrum β-lactam antibiotic, amoxicillin, using the β-lactamase inhibitor, relebactam, in combination 
with imipenem. We establish synergy between amoxicillin, relebactam and imipenem, as well as activity against 
a range of M. abscessus clinical isolates. We have identified the mechanism of relebactam-BlaMab inhibition as 
competitive using recombinant protein in both a novel thin-layer chromatography (TLC)-based assay, as well as 
previously established spectrophotometric methods. Furthermore, this has been delineated using in silico molec-
ular docking. This offers a considerable therapeutic potential as imipenem, a mainstay of current M. abscessus 
treatment, in combination with relebactam and cilastatin has recently been approved by the U.S. Food and Drug 
Administration (FDA) for use against urinary tract and intra-abdominal infections25. Therefore, the addition of 
amoxicillin in conjunction with the repurposing of relebactam alongside imipenem, to the current treatment 
regime has the potential to significantly improve treatment outcome.
Results
In vitro testing of amoxicillin-imipenem-relebactam on M. abscessus. In this paper we have iden-
tified that M. abscessus can be made susceptible to amoxicillin by the addition of the competitive β-lactamase 
inhibitor, relebactam. We have further demonstrated that when used in conjunction with amoxicillin, the MIC 
of the imipenem-relebactam combination can be significantly reduced. This effect is not as pronounced in cef-
tazidime-avibactam in combination with amoxicillin. We also show that meropenem susceptibility can also be 
enhanced by the addition of relebactam. Firstly, we conducted disk diffusion assays with amoxicillin and mero-
penem, with and without relebactam (Fig. 1a). Subsequently the zones of inhibition (ZOI) were measured as a 
marker of susceptibility. Amoxicillin alone failed to demonstrate any kind of susceptibility, however the addition 
of relebactam provided a clear ZOI, demonstrating the induced susceptibility to amoxicillin by relebactam. A 
small ZOI was visible for meropenem, however with the incorporation of relebactam, this ZOI was enhanced, 
suggesting increased susceptibility upon combination with relebactam (Fig. 1a). In order to assess the clinical 
relevance of these observations, both amoxicillin and meropenem were tested alone and in combination with rel-
ebactam against a panel of clinical isolates of M. abscessus obtained from patients at Brighton and Sussex Medical 
School, in addition to M. abscessus NCTC strain. In all cases, the addition of relebactam resulted in the isolate 
becoming susceptible amoxicillin (n = 3) (Fig. 1b left). The same experiment was conducted with meropenem, 
and in most cases, an increase in susceptibility was observed (n = 3) (Fig. 1b right). All necessary controls were 
conducted and no ZOI was observed for relebactam alone.
In order to further validate our observation, liquid cultures were exposed to increasing concentrations of 
amoxicillin and meropenem with and without a dose response of relebactam (Fig. 1c). As a control, relebactam 
was also tested for inhibitory activity on its own. Relebactam at 128 mg/L demonstrated no inhibitory activity, 
giving a growth profile much the same as the compound-free control (no drug), confirming that relebactam lacks 
antibacterial activity against M. abscessus. 32 mg/L of amoxicillin appeared to show a moderate enhancement of 
bacterial growth, however when combined with 2 mg/L of relebactam, this amoxicillin concentration was found 
to display potent antibacterial activity against M. abscessus (Fig. 1c). The same experiment was conducted with 
meropenem, wherein partial growth impairment was observed at 8 mg/L, however when combined with 2 mg/L 
relebactam, significant antibacterial activity was observed at this concentration. End point statistical analysis was 
conducted using a t-test to assess the significance of differences between cultures with and without relebactam. In 
both cases, a statistically significant increase in susceptibility was observed upon addition of 2 mg/L of relebactam 
in combination with amoxicillin or meropenem.
Since relebactam is only available in combination with imipenem, experiments with amoxicillin in conjunc-
tion with imipenem-relebactam were conducted, alongside amoxicillin and ceftazidime-avibactam (Fig. 1d top 
and bottom respectively). Both of these β-lactam/ β lactamase inhibitor combinations are commercially approved 
by the FDA, however their efficacies against M. abscessus are yet to be compared. An experiment was conducted 
using a fixed ratio of imipenem-relebactam with and without amoxicillin, representative of the ratio of these 
drugs in the approved combination. At concentrations of 0.5:0.25 mg/L imipenem:relebactam without amoxi-
cillin, growth was observed to be similar to that of the M. abscessus cells only control, whereas with the addition 
of 32 mg/L amoxicillin, total inhibition of growth is seen. A similar experiment was conducted using ceftazidi-
me:avibactam with and without amoxicillin. Inhibition was observed at ceftazidime:avibactam 32:32 mg/L with 
the addition amoxicillin 8 mg/L, and those same concentrations with no amoxicillin were again similar to the no 
drug control.
In vitro antibiotic susceptibility testing was performed for imipenem, amoxicillin and relebactam, either on 
their own, in conjunction with each other, or as a triplicate combination, against 16 M. abscessus clinical isolates, 
M. abscessus containing the BlaMab constitutive overexpression plasmid pVV16-blaMab and M. abscessus pVV16 
(Table 1). All but one isolate (93.75%) had MICs of >128 mg/L for amoxicillin and >32 mg/L for relebactam, 
indicating these isolates are not susceptible to these drugs within their reasonable clinical range. When com-
bining amoxicillin with relebactam, 81.25% of the strains became susceptible to amoxicillin, with MICs ranging 
from 4–128 mg/L, requiring 0.5–16 mg/L of relebactam to produce this effect. The imipenem MICs ranged from 
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2–8 mg/L, therefore according to CLSI breakpoint guidelines, all of the clinical isolates were susceptible or inter-
mediate to imipenem.
M. abscessus pVV16-blaMab had an MIC of imipenem of 32 mg/L. When combining imipenem with rele-
bactam (MIC range 1–2 mg/L), the MICs of imipenem were reduced 2-fold in 43.75% of the clinical isolates, 
produced no effect in 31.25% of the clinical isolates and surprisingly, increased the MIC of imipenem 2-fold 
in 6.25% of the clinical isolates. The MIC of imipenem against M. abscessus pVV16-blaMab was reduced 4-fold 
from 32 mg/L to 8 mg/L with the addition of 4 mg/L relebactam. The MIC of imipenem against M. abscessus 
pVV16 was unchanged at 2 mg/L. When imipenem and relebactam (MIC range 0.25–1 mg/L) were combined 
with amoxicillin (MIC range 8–128 mg/L), the MICs of imipenem reduced 2-fold in 18.75% of the clinical iso-
lates, 4-fold in 62.5% of the clinical isolates, 8-fold in 12.5% of the clinical isolates, remained the same in 6.25% of 
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Figure 1. Relebactam makes Mycobacterium abscessus susceptible to amoxicillin and increases susceptibility 
to meropenem. (1a) A disk diffusion experiment and corresponding plate map demonstrating enhanced 
susceptiblity of M. abscessus (NCTC) by zone of inhibition to amoxicillin (1) with the addition of relebactam 
(2) and meropenem (3) with the addition of relebactam (4). (1b) The disk diffusion experiments were 
conducted with the NCTC M. abscessus strain along with a panel of clinical isolates, demonstrating enhanced 
susceptibility by addition of relebactam (REL) to amoxicillin (AMX) and meropenem (MEM). (1c) Growth 
curves were conducted with M. abscessus NCTC in medium containing 128 mg/L relebactam only and 32 mg/L 
amoxicillin with and without relebactam at 2 mg/L. Growth inhibition was only observed with relebactam 
in combination with amoxicillin. Likewise, the inhibitory activity of meropenem was clearly enhanced with 
the addition of relebactam. A t-test was used for end point analysis between samples +/− relebactam and the 
results were deemed to be significant with p values of <0.0001 and 0.0152 for amoxicillin and meropenem 
respectively. (1d) Growth curves were conducted with M. abscessus NCTC in medium containing 0.5 mg/L 
imipenem and 0.25 mg/L relebactam, with and without amoxicillin at 32 mg/L. The inhibitory activity of 
imipenem-relebactam was enhanced with the addition of amoxicillin (p = 0.0028). Growth curves were also 
conducted with M. abscessus NCTC in medium containing 32 mg/L ceftazidime and 32 mg/L avibactam, 
with and without amoxicillin at 8 mg/L. The inhibitory activity of ceftazidime-avibactam was enhanced by 
amoxicillin but to a lesser extent than imipenem-relebactam (p = 0.0016).
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the clinical isolates and reduced 16-fold in M. abscessus pVV16-blaMab compared with imipenem alone. Briefly, 
the MIC ranges for imipenem alone in our isolates was 2–8 mg/L, which was reduced to 2–4 mg/L with the addi-
tion of relebactam (aside from M. abscessus pVV16-blaMab which has an MIC of 8 mg/L), and further reduced to 
0.5–4 mg/L with the addition of both relebactam and amoxicillin. The MIC ranges for amoxicillin were generally 
higher and more variable than those of imipenem, with an MIC range of 4–128 mg/L with the addition of rele-
bactam, with some isolates lacking susceptibility at the highest concentration tested. The addition of both rele-
bactam and imipenem resulted in an MIC range of 4–128 mg/L. This result is replicated using the ZOI method, 
which clearly demonstrated drug-target interaction between relebactam and BlaMab, as no activity of amoxicillin 
is seen. Plate images and plate map for the subsequent resistance induced by BlaMab overexpression are shown in 
Supplementary Figure 1.
Although 93.75% of M. abscessus clinical isolates are resistant to amoxicillin on its own, with MICs 
of >128 mg/L, the results in Table 1 show that amoxicillin susceptibility in M. abscessus isolates can be seen 
with the addition of the β-lactam inhibitor, relebactam. It is also well established that imipenem is effective 
against most strains of M. abscessus, but the results from Table 1 clearly show that the efficacy of imipenem can be 
enhanced with the addition of relebactam, and further enhanced with the addition of relebactam and amoxicillin.
Biochemical analysis of relebactam inhibition of M. abscessus β-lactamase. In order to validate 
the inhibitory activity observed phenotypically in Fig. 1, we conducted biochemical analysis of the activity of 
relebactam on the M. abscessus endogenous β-lactamase, BlaMab. The gene was amplified by PCR, digested, ligated 
into pET28a and sequenced, before transformation into chemically competent E. coli BL21. BlaMab was expressed, 
cells harvested and the enzyme purified by IMAC. We subsequently devised a novel TLC-based assay for assessing 
β-lactamase activity by separating the penicillin V substrate from the penicilloic acid product. This assay enabled 
us to demonstrate the β-lactamase activity of our purified BlaMab (Fig. 2a), as well as assay the efficacy of inhibitors 
against the enzyme (Supplementary Fig. 2a,b). We used avibactam as a positive control, as its inhibitory activity 
against BlaMab has previously been described by Dubée et al.19. Lane 1 contained protein purification buffer only, 
and lane 2 had the addition of enzyme (0.01 mg/mL). Following chromatography, two lower spots are observed in 
lanes 1 and 2, indicative of buffer. Penicillin V was added to lane 3 and gave a characteristic spot of high Rf value, 
demonstrating unhydrolysed penicillin resulted in a spot just below the solvent front. Lane 4 was identical to 
lane 3 with the addition of BlaMab protein. The hydrolysis of penicillin V to penicilloic acid by BlaMab resulted in a 
spot with reduced Rf value. The pre-incubation of enzyme with avibactam in lane 5 resulted in a loss of the lower 
penicilloic acid spot, demonstrating the inhibition of BlaMab activity. In lane 6, relebactam alone did not resolve 
on the TLC, but its pre-incubation with BlaMab before addition to the penicillin substrate in lane 7 resulted in total 
inhibition of hydrolysis as observed with avibactam (lane 5). Finally, the inhibition of BlaMab is further validated 
by the repeat of lane 4 and lane 7 conditions with heat-denatured BlaMab (lanes 8 and 9 respectively). This result 
confirms the direct inhibition of BlaMab by relebactam (n = 5).
We investigated the kinetic parameters of the Michaelis-Menten kinetics, the apparent Ki (Ki app), the 
second-order carbamylation rate constant (k2/Ki) and the decarbamylation rate constant (koff) of relebactam 
inhibition of soluble recombinant BlaMab using a commercially available β-lactamase substrate, nitrocefin, as a 
M. abscessus 
strain
MIC (mg/L)
AMX IMI REL
AMX 
(+REL)
IMI 
(+REL)
REL 
(+AMX)
REL 
(+IMI)
AMX 
(+IMI 
+REL)
IMI 
(+AMX+REL)
REL 
(+AMX 
+IMI)
NCTC >128 2 >32 64 2 2 1 32 0.5 0.25
DC088 A >128 4 >32 128 2 >32 1 64 1 0.5
DC088 B >128 4 >32 32 4 >32 2 32 1 0.5
DC088 C >128 8 >32 >128 4 >32 2 32 1 0.5
DC088 D >128 4 >32 >128 4 >32 2 4 2 1
DC088 E >128 2 >32 128 2 16 1 64 1 0.5
DC088 Ref >128 4 >32 >128 2 >32 1 64 1 0.5
211666 >128 4 >32 128 2 8 1 64 1 0.5
137071 >128 2 >32 128 4 16 2 16 2 1
199277 >128 4 >32 64 4 16 2 128 1 0.5
194891 8 4 >32 4 2 0.5 1 64 1 0.5
159544 >128 4 >32 128 2 1 1 8 1 0.5
186433 >128 2 >32 128 4 32 2 128 1 0.5
186144 >128 8 >32 128 4 4 2 64 1 0.5
186154 >128 16 >32 >128 4 >32 2 8 4 2
147028 >128 4 >32 >128 4 >32 2 16 1 0.5
pVV16-blaMab >128 32 >32 128 8 16 4 0 2 4
pVV16 >128 2 >32 32 2 2 1 32 1 0.5
Table 1. Minimum Inhibitory Concentrations (MIC) of imipenem and/or amoxicillin in combination with 
relebactam against M. abscessus clinical isolates (including NCTC 13031) and M. abscessus pVV16-blaMab and M 
abscessus pVV16.
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Figure 2. Biochemical analysis of relebactam inhibition of M. abscessus β-lactamase, BlaMab. (2a) Our novel 
Thin Layer Chromatography (TLC) assay exhibiting the activity of BlaMab in the turnover of penicillin V (high 
Rf value) to penicilloic acid (lower Rf value). In the absence, or termination of activity of BlaMab (by boiling 
(100 °C) for 1 h) or addition of known inhibitor avibactam19,27 (200 µg/mL) no lower Rf value spot 
corresponding to penicilloic acid is resolved by TLC. The addition of relebactam to the reaction between 
BlaMab and penicillin V also results in the absence of the lower Rf value spot. (2b) This observed inhibition is 
validated by a spectrophotometric analysis. The increase in concentration of relebactam resulted in partial 
inhibition of nitrocefin turnover at 1 µM and total abrogation at 10 µM. The initial velocity (vi) of the reaction 
between BlaMab and nitrocefin was monitored for a range of substrate concentrations (1–500 µM) and 
relebactam concentrations (0, 0.5, 0.75, 1 and 2.5 µM). (2c) This data was plotted vi vs [S] in order to determine 
Km values. (2d) The values for kobs were obtained as previously described19 and plotted against relebactam 
concentrations ([I]) to deduce a carbamylation rate (k2/Ki) for BlaMab. (2e) The kinetics of BlaMab 
decarbamylation were assessed to show the recovery of nitrocefin hydrolysis by BlaMab after inhibition by 
relebactam in order to derive a koff value. (2 f) Kinetic parameters were derived as described previously19.
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reporter substrate. Nitrocefin is selectively hydrolysed by β-lactamases, resulting in an increase in absorbance 
which can be monitored at 486 nm. By pre-incubating BlaMab enzyme with a dose response of relebactam (from 
0–100 μM), before initiation of the absorbance assay with the addition of nitrocefin substrate, we observed partial 
inhibition at 1 μM (0.348 μg/mL) and a complete loss of activity at 10 μM (3.48 μg/mL), confirming the direct 
inhibitory activity of relebactam on BlaMab (Fig. 2b).
The initial velocities (vi) of nitrocefin turnover were recorded for a range of nitrocefin concentrations 
(1–500 µM) over a range of relebactam concentrations (0–2.5 µM). These results were plotted as classical 
Michaelis-Menten curves (vi vs [S]) (Fig. 2c), resulting in Michaelis constants (Km) between 69.43–16.96 µM, 
before initial velocities were abolished at 2.5 µM relebactam. However, we were unable to derive a Ki value using 
this data. In response, we plotted the reciprocal initial velocities against relebactam concentrations as a linear 
equation and derived Ki app observed from the Y intercept/slope, which was then normalised for the use of nitro-
cefin (Fig. 2f)26. The Ki app value obtained of 183.6 nM is indicative of the high inhibitory potency of relebactam 
against BlaMab. The carbamylation rate constant (k2/Ki) of 2.32 ×106 M−1s−1 is similar to the observed rate for 
avibactam inhibition of BlaMab (4.9 ×105 M−1s−1)20. The rate of decarbamylation (koff) of BlaMab for relebactam 
was 0.0146 min−1, which is again similar to the rate previously obtained for that of avibactam (0.047 min−1)19. 
Our kinetics analysis show that, like avibactam, relebactam is a potent, competitive and reversible inhibitor of 
BlaMab, displaying a reasonably rapid “on” rate and slow “off ” rate, with only half the enzyme recovering activity 
after 40 minutes in the absence of relebactam (Fig. 2e)19.
Our TLC-based β-lactamase assay enabled us to further explore the parameters of the inhibitory activity of 
relebactam by varying the time of pre-incubation of relebactam with BlaMab (Supplementary Fig. 2a) and the 
minimum inhibitory concentration required to abrogate catalytic turnover of the penicillin V substrate to the 
penicilloic acid product (Supplementary Fig. 2b). We found that penicillin V turnover was rapid and that only 
addition of relebactam at the same time as the substrate demonstrated turnover of penicillin V, suggesting com-
petitive, reversible inhibition of BlaMab by relebactam. The dose response of relebactam demonstrated total inhi-
bition down to 20 µg/mL, and activity of BlaMab was maintained below a relebactam concentration of 2 µg/mL. 
This suggested a minimal concentration of relebactam required to inhibit BlaMab in the assay is 20 µg/mL, which 
corresponds to a less than or equal to 100 fold stoichiometric excess of relebactam required to completely inhibit 
BlaMab (0.5 µM BlaMab to 57.5 µM relebactam corresponding to 20 µg/mL).
In silico analysis of relebactam binding to M. abscessus β-lactamase. In order to further investigate 
the mechanism of relebactam inhibition of BlaMab, we conducted molecular docking simulations in silico. 6 poten-
tial binding sites were identified (Fig. 3c). For pockets 2–6 the ligand was weakly-held and generally exited the 
pocket after a few tens of nanoseconds. For pocket 1 (corresponding to the main active site) the ligand reoriented 
itself relative to the docked conformation and thereafter remained relatively stable within the pocket. The binding 
interactions for the stable pose are shown in Fig. 3(a,b) and include several polar interactions with the sulphona-
mide moiety and hydrophobic interactions between the relebactam central piperidine ring and tryptophan 106. 
In addition, after the initial reorientation, the relebactam carbonyl carbon remained in the vicinity of the hydroxyl 
oxygen of the catalytically-active serine 71 as can be seen after 120 ns in the distance plot given in Fig. 3(d). The 
average distance in this period was approximately 5.5 Å and there were many close approaches. Furthermore, the 
corresponding O-C=O angle (Fig. 3d) in the same period was roughly 130° and as such it is reasonable to assume 
that it would be possible for the serine hydroxyl to attack the relebactam carbonyl and effect a ring-opening. A 
further molecular dynamics simulation of the enzyme in a periodic box of explicit water was undertaken but this 
time in the presence of ten copies of unbound relebactam. Over the course of a 200 ns simulation, one ligand 
found its way into the main active site (pocket 1) after 130 ns and remained stable therein. The other nine copies 
of the ligand found no place to reside in the enzyme.
Discussion
In this paper we have demonstrated the inhibitory activity of the non-β-lactam based β-lactamase inhibitor, 
relebactam, against the endogenous M. abscessus β-lactamase, BlaMab, resulting in increased susceptibility of the 
organism to β-lactam activity. Inhibition of BlaMab only is not sufficient to kill M. abscessus, but this does open up 
the ability to utilise a wider range of β-lactam antibiotics, therefore the use of relebactam as part of a drug com-
bination represents considerable therapeutic potential. We have identified that a low concentration of relebac-
tam co-administration is capable of making M. abscessus NCTC and clinical isolates susceptible to amoxicillin, 
well within the therapeutic range for this versatile and widely available antibiotic. Relebactam has recently been 
approved by the FDA for administration in combination with imipenem, a mainstay in M. abscessus front line 
chemotherapy, and cilastatin. In conjunction with imipenem, the concentration of relebactam and amoxicillin 
required to combat M. abscessus are reduced further. Meropenem was not utilised within this triplicate com-
pound combination, since imipenem has been previously shown to be the most effective carbapenem against M. 
abscessus, whereas amoxicillin has a broader range of activity against penicillin-binding proteins24.
Despite being an important component of M. abscessus treatment, imipenem is considered a last-resort anti-
biotic and is associated with severe side effects and toxicity, so it is therefore in the patients interest to provide the 
lowest possible dosage28. The addition of amoxicillin reduces the concentration of imipenem-relebactam needed 
to observe an inhibitory effect by 4-fold, indicating its potential as a combination therapy that maximises the 
inhibitory effect, whilst reducing the superfluous chemotherapeutic burden to the patient. Interestingly, the same 
could not be observed with the ceftazidime-avibactam combination. Whilst the addition of amoxicillin enhanced 
the inhibitory effect, relatively higher concentrations of ceftazidime-avibactam are needed, reducing its therapeu-
tic potential as combination therapy against M. abscessus disease. This is of note, since relebactam is a derivative 
of avibactam, the difference in inhibition efficacy is unusual29. This is possibly due to the additive effect between 
amoxicillin and imipenem alongside relebactam aiding in reducing the overall inhibitory concentrations, whereas 
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the combination of ceftazidime-avibactam is less potent since M. abscessus is more resistant to ceftazidime than 
imipenem, reducing this additive effect22.
The data in Table 1 shows that across all clinical isolates that were examined, the concentrations of both amox-
icillin and imipenem required to inhibit bacterial growth were significantly reduced upon the addition of rele-
bactam. This suggests that all clinical isolates are expressing BlaMab endogenously, despite a single isolate (194891) 
showing a higher susceptibility to amoxicillin before addition of relebactam, suggesting this isolate has a lower 
expression level than the others. The combination of all three drugs resulted in an additional reduction in con-
centration of amoxicillin, imipenem and relebactam repespectively. The data also shows that the overexpression 
of BlaMab results in the MIC of both amoxicillin and imipenem increasing, and that, in turn, higher concentra-
tions of relebactam are required to overcome this synthetic resistance. This clearly demonstrates whole cell target 
engagement and inhibition of BlaMab by relebactam. Previous research, which assessed the concentrations of these 
compounds that can be achieved in the epithelial lining fluid (ELF) of alveoli, suggests that the MICs reported 
in Table 1 would be able to be reached during treatment of patients30. In a phase I trial, the ELF concentrations 
of relebactam and imipenem achieved after multiple dose treatment (at 250 mg REL and 500 mg IMI) have been 
reported to be 15 µM (5.23 mg/L) and 32 µM (9.58 mg/L) respectively, which are well above the MICs required to 
inhibit M. abscessus growth reported in Table 130.
Our study introduces a novel TLC-based β-lactamase inhibition assay, validated with the commercially avail-
able and widely used nitrocefin assay, to investigate the parameters of relebactam′s inhibitory activity. The results 
of both the kinetics analysis and the in silico binding studies demonstrate the mechanism of inhibition of BlaMab 
by relebactam as competitive reversible, displaying a reasonably rapid “on” rate and slow “off ” rate, indicative of 
the high potency of the inhibitor against BlaMab.
Our findings represent a timely and highly impactful discovery that could be easily translatable into the clini-
cal setting, providing a new therapeutic option for M. abscessus infections.
Materials and Methods
Bacterial isolates. A total of 16 M. abscessus clinical isolates from Brighton and Sussex Medical School 
and M. abscessus NCTC 13031 were used in this study. Stock solutions of the isolates were kept in 50% glycerol 
(Sigma, Dorset, UK) and Middlebrook 7H9 Broth and stored at −80 °C. Isolates were grown in Middlebrook 
7H9 medium supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC), 1% glycerol (50% w/v) and 
Figure 3. In silico modelling of the possible interaction of relebactam with the M. abscessus β-lactamase, 
BlaMab. (3a and 3b) 3D and 2D protein-ligand interaction diagrams for relebactam in the main (catalytic) 
active site after molecular dynamics simulation. Amino acid residues featured in the top six potential binding 
pockets identified for BlaMab. (3c) Pocket 1 corresponded to the main (catalytic site) in the enzyme and for 
the purposes of the docking experiment was redefined as all amino acid residues within 8 Å of serine 71. Time-
courses of the serine 71 hydroxyl oxygen – relebactam carbonyl carbon distance and the corresponding O-C=O 
angle. (3d) The actual values are plotted as black points and a 50-frame moving average is over-plotted in red.
8Scientific RepoRtS |          (2020) 10:928  | https://doi.org/10.1038/s41598-020-57844-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
0.05% Tween 80 (v/v) prior to testing. Escherichia coli Top 10 cells were used for propagation of plasmid DNA. 
These cells were routinely grown in nutrient broth, or nutrient agar (Oxoid, UK) at 37 °C. E. coli BL21 (DE3) cells 
were used for the overproduction of recombinant protein, grown in Terrific Broth (Melford, UK) at 37 °C.
Antimicrobials. The antimicrobial agents meropenem (MEM), amoxicillin (AMX) and phenoxymethylpen-
icillin (Penicillin V/PenV) were obtained from Sigma Aldrich (Dorset, UK) and relebactam (REL), imipenem 
(IMI) and avibactam (AVI) were obtained from Carbosynth (Compton, UK). Stock solutions were prepared in 
sterile de-ionised water and stored at −20 °C until use.
Disk diffusions. For the disk diffusion assays, M. abscessus clinical isolates were grown in Middlebrook 7H9 
Broth to logarithmic phase and 100 µL of bacterial culture was inoculated into 10 mL Middlebrook 7H9 Broth sup-
plemented with 0.7% bacteriological agar. This was poured as a layer in agar plates on top of 15 mL Middlebrook 
7H11 Agar supplemented with 10% OADC and 1% glycerol. 6 mm sterile filter paper diffusion disks were placed 
on the agar and were subsequently impregnated with antibiotic at the following concentrations in sterile dis-
tilled water: relebactam 1 µL of 10 mg/mL, amoxicillin 3.3 µL of 3 mg/mL and meropenem 1 µL of 10 mg/mL. 
Plates were incubated at 30 °C for 5 days or until clear zones of inhibition were visualised. Zones of inhibition 
were measured across the diameter to include the disk itself in mm. Disk diffusions were also performed on 
M. abscessus pVV16-blaMab and M. abscessus pVV16.
Broth microdilution assay. The broth microdilution assay was performed as described previously with 
alterations appropriate to this study31,32. Plates were prepared by serially diluting amoxicillin (128 mg/L–0 mg/L) 
or meropenem (128 mg/L–0 mg/L) in the x-axis and either relebactam (32 mg/L–0 mg/L) or relebactam: imipe-
nem (32: 64 mg/L–0 mg/L) or avibactam: ceftazidime (128: 128 mg/L–0 mg/L) in the y-axis. 80 µL of M. abscessus 
NCTC 13031 suspension adjusted to an OD600 of 0.1–0.2 was inoculated in each well to reach a final well volume 
of 100 µL. Assay plates containing amoxicillin and/or imipenem with or without relebactam were also tested 
against 15 other clinical isolates and M. abscessus pVV16 blaMab and M. abscessus pVV16.
Plates were sealed and incubated at 30 °C for 3–5 days. The minimum inhibitory concentrations (MICs) of 
the various combinations were determined by optical density measurement using a spectrophotometric plate 
reader and identified as the well that had the lowest concentrations of both compounds and exhibited no bacterial 
growth (for imipenem susceptibility testing, CLSI breakpoints were utilised (Institute, Clinical and Laboratory 
Standards 2012). The relevant well was retroactively plotted into a growth curve over time, and this growth curve 
was compared to the wells containing no drug, and the wells containing either relebactam, relebactam-imipenem 
or ceftazidime-avibactam only and amoxicillin only. The broth microdilution assay was also performed on M. 
abscessus pVV16-blaMab and M. abscessus pVV16.
Generation of M. abscessus pVV16-blaMab overexpressor strain. The blaMab gene (MAB_2875) from 
M. abscessus NCTC 13031 was amplified by polymerase chain reaction (PCR). Primers used were as follows (with 
restriction site underlined): Forward primer AAAAAAGGATCCGCGCCGGACGAACTCGCC and Reverse 
primer AAAAAAAAGCTTAGCGCCGAAGGCCCGCAG (Eurofins Genomics). Amplicons were purified and 
cloned into pVV16 using BamHI/HinDIII restriction sites and the correct sequence was confirmed by DNA 
sequencing (Eurofins Genomics). Both the plasmid pVV16 and the construct pVV16-blaMab were inserted into 
M. abscessus NCTC 13031 cells by electroporation (2.5 kV, 25 µF and 1000 Ω).
Expression and purification of recombinant BlaMab. The blaMab gene, with the first 90 base pairs omit-
ted (resulting in a −30 residue N-terminal truncated protein), was amplified by PCR using the following prim-
ers (with restriction sites underlined): Forward primer AAAAAAGGATCCGCGCCGGACGAACTCGCC and 
Reverse primer AAAAAAAAGCTTTCAAGCGCCGAAGGCCCG (Eurofins Genomics). Amplicons were puri-
fied and cloned into pET28a using BamHI/HinDIII restriction sites and the correct sequence was confirmed by 
DNA sequencing (Eurofins Genomics). BlaMab was expressed in E. coli BL21 (DE3) cells by addition of 1 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubation at 25 °C for 18 h. BlaMab (6×-His tagged) was 
purified by Ni2+ Immobilised Metal Affinity Chromatography (IMAC) and dialysed into 25 mM Tris HCl pH 7, 
100 mM NaCl.
Thin Layer Chromatography (TLC) activity assay. Relebactam (2 mg/mL) was added to recombinant 
BlaMab (0.01 mg/mL) and incubated for 5 min at room temperature, before addition of Penicillin V (4 mg/mL) for 
a further 10 min incubation at room temperature. Alongside appropriate control reactions (Fig. 2a), 1 µL of the 
reaction was spotted onto aluminium backed silica gel plates (5735 silica gel 60 F254, Merck) and dried before being 
subjected to Thin Layer Chromatography (TLC) using ethyl acetate:water:acetic acid (C4H8O2:H2O:CH3COOH) 
(3:1:1, v/v/v). Once dry, plates were visualised by being dipped into KMnO4 TLC stain with light charring.
Biochemical analysis of BlaMab inhibition by relebactam. Recombinant BlaMab (0.25 nM) was mixed 
with an increasing concentration of relebactam (0, 0.1, 1, 10 and 100 µM) and 100 µM nitrocefin (Carbosynth, 
UK). The hydrolysis of nitrocefin was monitored at 486 nm using a Multiskan Go plate reader (Thermo Scientific). 
This was repeated using a varying concentration of nitrocefin (1–500 µM) with a shorter range of relebactam 
concentrations (0, 0.5, 0.75, 1 and 2.5 µM) and initial velocities (vi) were plotted against substrate concentration. 
Data analysis was performed as previously described22,26. Data analysis was conducted using Graphpad Prism 7.
The decarbamylation rate was determined by incubation of BlaMab (1 µM) with relebactam (20 µM) for 1 hour 
at 25 °C. The reaction mixture was then subsequently diluted both 10,000 and 50,000 fold (1.8 nM and 0.36 nM 
relebactam with 90 pM and 18 pM BlaMab respectively), before addition of 100 µM nitrocefin. The reaction was 
monitored at 486 nm using a Multiskan Go plate reader (Thermo Scientific).
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In silico modelling of the possible interaction of relebactam with the BlaMab. The BlaMab X-ray 
crystal structure was obtained from the Protein Data Bank, accession code 4YFM. The A chain was submit-
ted to the GHECOM pocket-finding server (GHECOM 1.0)33,34. The top six pockets identified were used to 
define the target site for protein-ligand docking experiments between the enzyme and relebactam using CACHe 
Worksystem Pro (version 7.5.0.85, Fujitsu Ltd). The amino acid residues lining these pockets are given in Fig. 3(c). 
Pocket 1 corresponded to the main (catalytic) site in the enzyme and for the purposes of the docking experiment 
was redefined as all amino acid residues within 8 Å of serine 71. Hydrogen atoms were added using the default 
settings in line with presumed protonation states for ionisable amino acid side-chains. The positions of the added 
hydrogen atoms were optimised by locking the coordinates of all the non-hydrogen atoms and subjecting the 
system to a molecular mechanics (MM2) geometry optimisation. Relebactam was docked four times into each 
pocket, using CACHe Worksystem Pro. The amino acid side-chains in each pocket were allowed to be flexible as 
were all rotatable bonds in relebactam. The genetic algorithm settings for the docking protocol included popula-
tion size 50, maximum generations 3000, crossover rate 0.8, mutation Rate 0.2 and convergence when the RMSD 
population fitness was less than 1. The best-scoring consensus complexes from each series of dockings were taken 
forward for molecular dynamics simulation. The required input files were prepared using the Antechamber mod-
ule of the AMBER Tools package (Version 1435), implementing the ff14SB force field. The system was neutralised 
by addition of sodium ions and then solvated within a truncated octahedron of TIP3P water molecules extending 
8 Å from the surface of the protein. Using the Amber 14 molecular dynamics package CUDA version36–38, the sys-
tem was energy-minimised for 2,000 cycles using a non-bonded cut-off of 12 Å and then heated under constant 
volume to 300 K over 25 ps under Langevin dynamics (time step = 1 fs). The heating was continued at 300 K for 
at least 200 ns under constant pressure also using Langevin dynamics (SHAKE on, time step = 2 fs) using the 
Particle–Mesh–Ewald (PME) method to treat the long range electrostatic interactions with a 12 Å non-bonded 
cut-off.
Data availability:
All data will be made freely available by the authors upon request.
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